Loading...
Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide
BACKGROUND: Prostate cancer that recurs after initial treatment inevitably progresses to castration‐resistant prostate cancer (CRPC), the lethal stage of the disease. Despite improvements in outcomes from next generation androgen receptor (AR)‐axis inhibitors, CRPC remains incurable. Therapeutic str...
Na minha lista:
| Udgivet i: | Prostate |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6617752/ https://ncbi.nlm.nih.gov/pubmed/31228231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23843 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|